Peter Grootenhuis
Dutch-American Medicinal Chemist
Peter Grootenhuis's AcademicInfluence.com Rankings
Download Badge
Chemistry
Peter Grootenhuis's Degrees
- PhD Medicinal Chemistry University of Amsterdam
- Masters Chemistry University of Amsterdam
- Bachelors Chemistry University of Amsterdam
Why Is Peter Grootenhuis Influential?
(Suggest an Edit or Addition)According to Wikipedia, Peter Grootenhuis was a Dutch-American Medicinal Chemist. Grootenhuis was the Project Leader and Co-Inventor of Ivacaftor , the first CFTR potentiator FDA approved drug to treat the underlying cause of Cystic Fibrosis in patients with certain mutations in the Cystic Fibrosis Transmembrane Conductance Regulator gene , who account for 4-5% of CF cases. Grootenhuis also led the Vertex team to subsequent discovery of Orkambi, the combination of Ivacaftor and Lumacaftor, approved to treat CF in people with two copies of the F508del mutation . Most recently, Grootenhuis's team discovered Tezacaftor and Elexacaftor , which in combination with Ivacaftor are the components of Trikafta, a drug approved by the FDA in 2019 to treat CF in more than 90% of CF patients. For Grootenhuis’ contributions to the discovery of these compounds, he was awarded the 2018 IUPAC Richter Prize, the American Chemical Society’s 2013 Heroes of Chemistry Award, and inducted into the American Chemical Society Division of Medicinal Chemistry Hall of Fame. Grootenhuis has contributed to the discovery of over 11 clinical candidates, co-authored more than 100 peer reviewed papers and is inventor of 65 + U.S Patents, and more than 50 EU Patents.
Other Resources About Peter Grootenhuis
What Schools Are Affiliated With Peter Grootenhuis?
Peter Grootenhuis is affiliated with the following schools:
